MicroPort NeuroScientific Corporation (2172.HK) Stock

About MicroPort NeuroScientific Corporation

MicroPort NeuroScientific Corporation provides neuro-interventional medical devices. The company provides NUMEN Silk, a electronically detachable coil; Numen Lighting, a coil embolization system; Numen Nest, a detachable coil; NuFairy absorbable coil embolization system; Tubridge, a flow-diverting stent; Tubridge Plus, a flow-diverting stent; WILLIS, a intracranial stent graft system; Comaneci, a embolization assist device; and Rebridge, an intracranial visualized stent for intracranial aneurysm, as well as liquid embolic agent for cerebral arteriovenous malformations. It also offers APOLLO intracranial stent system for intracranial atherosclerosis; Bridge rapamycin target eluting and Bridge MAX rapamycin target eluting vertebral artery stent system for vertebral artery stenosis; Diveer intracranial balloon dilatation catheter, intracranial drug-coated balloon catheter system, intracranial self-expanding rapamycin target eluting stent, and intracranial balloon-expandable rapamycin target eluting stent for intracranial stenosis; and Carotid stent system, Safecer embolic protection device, and PathFinder carotid balloon dilation catheter for carotid artery stenosis. In addition, the company provides NeuroHawk thrombectomy device, NeuroHawk pass17/21 and medibox thrombectomy device and accessories, Tigertriever revascularization device, WAVE-track intracranial aspiration catheter, X-track intracranial distal access catheter, and NeuroGuard neurovascular balloon guide catheter for acute ischemic stroke. Further, it offers U-track intracranial support catheter system, Fastrack microcatheter system, QUEEN-track and 17 Microcatheter, Veyronwire neurovascular guide wire, Sheathru delivery catheter, and filter extension tube for single use. The company was founded in 2004 and is headquartered in Shanghai, China.

MicroPort NeuroScientific Corporation is led by CEO Zhiyong Xie, employs 547 people, headquartered in Shanghai, CN, publicly traded since 2022.

MicroPort NeuroScientific Corporation (2172.HK) stock trades at $8.99 with a market capitalization of $5.11B. The stock is valued at a price-to-earnings (P/E) ratio of 24.28, price-to-book of 2.51, price-to-sales of 6.46. Over the past 52 weeks the stock has ranged between $8.40 and $16.43, and currently trades 45.3% below its 52-week high. It pays a dividend yielding 1.56%.

On profitability, MicroPort NeuroScientific Corporation generates a return on equity (ROE) of 10.50%, an operating margin of 39.03%, a net profit margin of 23.34%.

Official website: www.microportneurosci.com